AI-driven small molecule discovery, which underlies most drugs on the market, is a challenge being tackled through science and technology ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

Xaira is an integrated biotechnology company built to deliver on the promise of AI to help transform the drug discovery and development process Dr. Ian McCaffery joins from AbbVie, where he served as ...

Tempus AI Inc. (NASDAQ:TEM) is one of the top 10 hidden AI stocks to buy. On May 31, Tempus AI launched the next generation ...

Design of targeted protein degraders is more than target degradation. Linker architecture, molecular flexibility, solubility, permeability, synthesis, purification, and formulation can all influence ...

Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeking a partner to support ...

A coalition of health experts has asked the Union government to urgently revise the NLEM. They say the delay is restricting affordable access to newer essential cancer and biological therapies.

Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...

Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical ...

The ongoing battle against neglected tropical diseases (NTDs) and pandemic pathogens such as COVID-19 has exposed significant deficiencies in our ...

The Trump administration sees the aid as more transactional - but some say it is not a fair trade.

U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the COVID-19 EUA declaration, effective June 29, ...